Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Disopyramide
Drug ID BADD_D00693
Description A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Indications and Usage For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.
Marketing Status approved
ATC Code C01BA03
DrugBank ID DB00280
KEGG ID D00303
MeSH ID D004206
PubChem ID 3114
TTD Drug ID D0M4YC
NDC Product Code Not Available
UNII GFO928U8MQ
Synonyms Disopyramide | Diisopyramide | Disopyramide Phosphate | Disopyramide Phosphate (1:1) | Disopyramide Phosphate (1:1), (+-)-Isomer | Disopyramide Phosphate (1:1), (R)-Isomer | Disopyramide Phosphate (1:1), (S)-Isomer | Disopyramide, (+-)-Isomer | Disopyramide, (R)-Isomer | Disopyramide, (S)-Isomer | Disopyramide, D-Tartrate (1:1), (S)-Isomer | Disopyramide, L-Tartrate (1:1), (R)-Isomer | Disopyramide, L-Tartrate (1:1), (S)-Isomer | Disopyramide, L-Tartrate (1:2), (+-)-Isomer | Disopyramide, L-Tartrate, (S)-isomer | Norpace | Palpitin | Palpitine | Rhythmodan | Ritmilen | Rythmilen | SC-13957 | SC 13957 | SC13957 | Disopyramide Monohydrochloride
Chemical Information
Molecular Formula C21H29N3O
CAS Registry Number 3737-09-5
SMILES CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia19.02.01.002; 17.15.03.002--
Jaundice cholestatic09.01.01.005--Not Available
Loss of consciousness17.02.04.0040.001911%Not Available
Malaise08.01.01.0030.011656%
Muscular weakness17.05.03.005; 15.05.06.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nasal dryness22.04.03.002--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neutropenia01.02.03.004--Not Available
Nodal rhythm02.03.03.021--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Pain08.01.08.004--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Palpitations02.11.04.0120.004204%
Paraesthesia23.03.03.094; 17.02.06.005--
Pollakiuria20.02.02.007--
Prostatism21.04.01.003; 20.02.03.009--Not Available
Pruritus23.03.12.001--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash morbilliform23.03.13.005--Not Available
Sensory loss17.02.07.007--Not Available
Shock24.06.02.002--Not Available
Sinus arrest02.03.03.007--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene